Search

Your search keyword '"Bulaj, Grzegorz"' showing total 463 results

Search Constraints

Start Over You searched for: Author "Bulaj, Grzegorz" Remove constraint Author: "Bulaj, Grzegorz"
463 results on '"Bulaj, Grzegorz"'

Search Results

52. The novel anticonvulsant neuropeptide and galanin analogue, NAX-5055, does not alter energy and amino acid metabolism in cultured brain cells

53. Circular logic: nonribosomal peptide-like macrocyclization with a ribosomal peptide catalyst

54. [mu]-Conotoxin KIIIA derivatives with divergent affinities versus efficacies in blocking voltage-gated sodium channels

55. Site-specific effects of diselenide bridges on the oxidative folding of a cystine knot peptide, [omega]-selenoconotoxin GVIA

56. Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor

57. Structure of the analgesic [mu]-conotoxin KIIIA and effects on the structure and function of disulfide deletion

58. NMR-based mapping of disulfide bridges in cysteine-rich peptides: application to the [mu]-conotoxin SxIIIA

59. Structure, dynamics, and selectivity of the sodium channel blocker [mu]-conotoxin SIIIA

60. Role of hydroxypyrolines in the in vitro oxidative folding and biological activity of conotoxins

61. Structure and sodium channel activity of an excitatory [I.sub.1]-superfamily conotoxin

62. Novel conotoxins from Conus striatus and Conus kinoshitai selectivity block TTX-resistant sodium channels

67. Propeptide does not act as an intramolecular chaperone but facilitates protein disulfide isomerase-assisted folding of a conotoxin precursor

68. Circular Logic: Nonribosomal Peptide-like Macrocyclization with a Ribosomal Peptide Catalyst

72. Conantokins Derived from the Asprella Clade Impart ConRl-B, an NMDA Receptor Antagonist with a Unique Selectivity Profile for NR2B Subunits

75. A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties

76. Neuroprotective and cardioprotective conopeptides: An emerging class of drug leads

79. Ribosomally synthesized and post-translationally modified peptide natural products : overview and recommendations for a universal nomenclature

84. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature

87. Patient-Empowerment Interactive Technologies

90. Conantokins Derived from the Asprella Clade Impart conRl-B, an N-Methyl d-Aspartate Receptor Antagonist with a Unique Selectivity Profile for NR2B Subunits

Catalog

Books, media, physical & digital resources